RESUMEN
In the current investigation, the physicochemical, biopharmaceutical and pharmacokinetic characterization of a new clofibric acid analog (Compound 1) was evaluated. Compound 1 showed affinity by lipophilic phase in 1 to 5 pH interval, indicating that this compound would be absorbed favorably in duodenum or jejunum. Also, Compound 1 possess two ionic species, first above of pH 4.43 and, the second one is present over pH 6.08. The apparent permeability in everted sac rat intestine model was 8.73 × 10-6 cm/s in duodenum and 1.62 × 10-5 cm/s in jejunum, suggesting that Compound 1 has low permeability. Elimination constant after an oral administration of 50 µg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 µg/mL at 0.33 h, AUC0-α was 956.54 µ/mL·h and distribution volume was 419.4 mL. To IV administration at the same dose, ke was 1.21 h-1, Vd was 399.6 mL and AUC0-α was 747.81 µ/mL·h. No significant differences were observed between pharmacokinetic parameters at every administration route. Bioavailability evaluated was 10.4%. Compound 1 is metabolized to Compound 2 probably by enzymatic hydrolysis, and it showed a half-life of 9.24 h. With these properties, Compound 1 would be considered as a prodrug of Compound 2 with potential as an antidiabetic and anti dyslipidemic agent.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Tetrazoles/química , Tetrazoles/farmacocinética , Administración Intravenosa , Administración Oral , Animales , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Ácido Clofíbrico/farmacocinética , Duodeno/metabolismo , Semivida , Hidrólisis , Hipoglucemiantes/farmacocinética , Hipolipemiantes/farmacocinética , Absorción Intestinal , Yeyuno/metabolismo , Masculino , Permeabilidad , Ratas , Ratas WistarRESUMEN
BACKGROUND: Fibrates are effective for modifying atherogenic dyslipidaemia, and particularly for lowering serum triglycerides. However, evidence that fibrates reduce mortality and morbidity associated with cardiovascular disease (CVD), or overall mortality and morbidity, in the primary prevention of CVD is lacking. OBJECTIVES: This Cochrane Review and meta-analysis aimed to evaluate the clinical benefits and harms of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of cardiovascular disease (CVD) morbidity and mortality. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and Web of Science (all from inception to 19 May 2016). We searched four clinical trial registers (last searched on 3 August 2016) with the help of an experienced professional librarian. We searched the databases to identify randomised controlled trials (RCTs) evaluating the clinical effects of fibrate therapy in the primary prevention of CVD events. We did not impose any language restrictions. SELECTION CRITERIA: We aimed to include all RCTs comparing the effects of fibrate monotherapy versus placebo or usual care, or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone. Included studies had a follow-up of at least six months for the primary prevention of CVD events. We excluded trials with clofibrate, because it was withdrawn from the market in 2002. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles and abstracts for potential study inclusion. Two review authors independently retrieved the full-text papers and extracted data. Disagreements were resolved by consensus. We calculated risk ratios (RRs) and accompanying 95% confidence intervals (CIs) for aggregate data on primary and secondary outcomes. We tested for heterogeneity with the Cochrane Q-test and used the I2 statistic to measure inconsistency of treatment effects across studies. Using the GRADE approach, we assessed the quality of the evidence and used the GRADE profiler software (GRADEpro GDT) to import data from Review Manager 5 to create 'Summary of findings' tables. MAIN RESULTS: We identified six eligible trials including 16,135 individuals. The mean age of trial populations varied across trials; between 47.3 and 62.3 years. Four trials included individuals with diabetes mellitus type 2 only. The mean treatment duration and follow-up of participants across trials was 4.8 years. We judged the risks of selection and performance bias to be low; risks of detection bias, attrition bias, and reporting bias were unclear. Reporting of adverse effects by included trials was very limited; that is why we used discontinuation of therapy due to adverse effects as a proxy for adverse effects. Patients treated with fibrates had a reduced risk for the combined primary outcome of CVD death, non-fatal myocardial infarction, or non-fatal stroke compared to patients on placebo (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.74 to 0.96; participants = 16,135; studies = 6; moderate-quality of evidence). For secondary outcomes we found RRs for fibrate therapy compared with placebo of 0.79 for combined coronary heart disease death or non-fatal myocardial infarction (95% CI 0.68 to 0.92; participants = 16,135; studies = 6; moderate-quality of evidence); 1.01 for overall mortality (95% CI 0.81 to 1.26; participants = 8471; studies = 5; low-quality of evidence); 1.01 for non-CVD mortality (95% CI 0.76 to 1.35; participants = 8471; studies = 5; low-quality of evidence); and 1.38 for discontinuation of therapy due to adverse effects (95% CI 0.71 to 2.68; participants = 4805; studies = 3; I2 = 74%; very low-quality of evidence). Data on quality of life were not available from any trial. Trials that evaluated fibrates in the background of statins (2 studies) showed no benefits in preventing cardiovascular events. AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that fibrates lower the risk for cardiovascular and coronary events in primary prevention, but the absolute treatment effects in the primary prevention setting are modest (absolute risk reductions < 1%). There is low-quality evidence that fibrates have no effect on overall or non-CVD mortality. Very low-quality evidence suggests that fibrates are not associated with increased risk for adverse effects.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Hipolipemiantes/uso terapéutico , Prevención Primaria , Atorvastatina/uso terapéutico , Bezafibrato/uso terapéutico , Enfermedades Cardiovasculares/mortalidad , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/uso terapéutico , Fenofibrato/uso terapéutico , Gemfibrozilo/uso terapéutico , Humanos , Hipolipemiantes/efectos adversos , Persona de Mediana Edad , Infarto del Miocardio/epidemiología , Infarto del Miocardio/mortalidad , Prevención Primaria/normas , Simvastatina/uso terapéutico , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/mortalidadRESUMEN
PPARα is a ligand activated transcription factor belonging to the nuclear receptor subfamily, involved in fatty acid metabolism in tissues with high oxidative rates such as muscle, heart and liver. PPARα activation is important in steatosis, inflammation and fibrosis in preclinical models of non-alcoholic fatty liver disease identifying a new potential therapeutic area. In this work, three series of clofibric acid analogues conjugated with naphthyl, quinolin, chloroquinolin and anthracenyl scaffolds were synthesized. In an effort to obtain new compounds active as PPARα agonists, these molecules were evaluated for PPARα transactivation activity. Naphthyl and quinolin derivatives showed a good activation of PPARα; noteworthy, optically active naphthyl derivatives activated PPARα better than corresponding parent compound.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , PPAR alfa/agonistas , Ácido Clofíbrico/farmacología , HumanosRESUMEN
Quantifying the characteristics of hormesis provides valuable insights into this low-dose phenomenon and helps to display and capture its variability. A prerequisite to do so is a statistical procedure allowing quantification of general hormetic features, namely the maximum stimulatory response, the dose range of hormesis, and the distance from the maximum stimulation to the dose where hormesis disappears. Applying extensions of a hormetic dose-response model that is well-established in plant biology provides a direct estimation of several quantities, except the hormetic dose range. Another dose range that is difficult to model directly is the distance between the dose where hormesis disappears and the dose giving 50% inhibition, known as toxic potency. The present study presents 2 further model extensions allowing for a direct quantification of the hormetic dose range and the toxic potency. Based on this, a 4-step mathematical modeling approach is demonstrated to quantify various dose-response quantities, to compare these quantities among treatments, and to interrelate hormesis features. Practical challenges are exemplified, and possible remedies are identified. The software code to perform the analysis is provided as Supplemental Data to simplify adoption of the modeling procedure. Because numerous patterns of hormesis are observed in various sciences, it is clear that the proposed approach cannot cope with all patterns; however, it should be possible to analyze a great range of hormesis patterns.
Asunto(s)
Hormesis , Modelos Estadísticos , Algoritmos , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/toxicidad , Contaminantes Ambientales/toxicidad , Hormesis/efectos de los fármacosRESUMEN
With reference to common application of HPLC to routine analytical tests on medicinal products decreasing the level of cholesterol, including three compounds from this group--fenofibrate, bezafibrate and etofibrate, we developed a new method for determining two other compounds--ciprofibrate and gemfibrozil. The developed HPLC method may be used for identification and qualitative determination of selected compounds--derivatives of aryloxyalkylcarboxylic acids as well as it may be used for simultaneous separation and determination of all compounds from the group of fibrates using one column and the same methodology. The results and statistical data indicate good sensitivity and precision. The RSD value presented is equivalent to the newly developed method of determinination of ciprofibrate and gemfibrozil in the substances and medicinal products--capsules and coated tablets.
Asunto(s)
Anticolesterolemiantes/análisis , Cromatografía Líquida de Alta Presión/métodos , Bezafibrato/análisis , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/análisis , Fenofibrato/análisis , Ácidos Fíbricos , Gemfibrozilo/análisisRESUMEN
The constitutive androstane receptor (CAR; NR1I3) is a key transcriptional factor that regulates genes encoding drug-metabolizing enzymes and drug transporters. However, studies on regulation of CAR target genes via up- or down-regulation of CAR are limited. In this study, we examined the effects of PPARalpha agonists (ciprofibrate, bezafibrate, fenofibrate and WY14643) on the expression of CAR and its target gene CYP2B1/2 in rat primary hepatocytes. Results from real-time PCR analysis showed that CAR and CYP2B1/2 mRNAs exhibit increases in response to all PPARalpha agonists studied (5 to 10-folds of control). Pretreatment of cells with cycloheximide, an inhibitor of protein synthesis, completely suppressed increase in CYP2B1/2 mRNA in response to ciprofibrate, suggesting that protein synthesis is required in this process. In addition, the induction of CAR by ciprofibrate on the protein level was observed with nuclear extracts as well as total cell lysates. These results indicate that CYP2B1/2 mRNAs are induced by PPARalpha agonists and that this effect is accompanied by increase in the expression of CAR gene at both mRNA and nuclear protein levels. Activated PPARalpha may increase functional CAR protein, which can induce the expression of CAR target genes such as CYP2B.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas/biosíntesis , Citocromo P-450 CYP2B1/biosíntesis , Regulación Enzimológica de la Expresión Génica , PPAR alfa/agonistas , Receptores Citoplasmáticos y Nucleares/biosíntesis , Esteroide Hidroxilasas/biosíntesis , Animales , Hidrocarburo de Aril Hidroxilasas/genética , Técnicas de Cultivo de Célula , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/antagonistas & inhibidores , Ácido Clofíbrico/farmacología , Receptor de Androstano Constitutivo , Cicloheximida/farmacología , Citocromo P-450 CYP2B1/genética , Interacciones Farmacológicas , Inducción Enzimática/efectos de los fármacos , Inducción Enzimática/genética , Ácidos Fíbricos , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Receptores Citoplasmáticos y Nucleares/genética , Esteroide Hidroxilasas/genéticaRESUMEN
BACKGROUND: CETP is a plasma protein that modulates atherosclerosis risk through its HDL-cholesterol reducing action. The aim of this work was to examine the effect of the PPARalpha agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo) CIII induced hypertriglyceridemia, and its impact on the HDL metabolism. RESULTS: Mice expressing apo CIII and/or CETP and non-transgenic littermates (CIII, CIII/CETP, CETP, non-Tg) were treated with ciprofibrate during 3 weeks. Drug treatment reduced plasma triglycerides (30-43%) and non-esterified fatty acids (19-47%) levels. Cholesterol (chol) distribution in plasma lipoprotein responses to ciprofibrate treatment was dependent on the genotypes. Treated CIII expressing mice presented elevation in VLDL-chol and reduction in HDL-chol. Treated CETP expressing mice responded with reduction in LDL-chol whereas in non-Tg mice the LDL-chol increased. In addition, ciprofibrate increased plasma post heparin lipoprotein lipase activity (1.3-2.1 fold) in all groups but hepatic lipase activity decreased in treated CETP and non-Tg mice. Plasma CETP activity and liver CETP mRNA levels were significantly increased in treated CIII/CETP and CETP mice (30-100%). Kinetic studies with 3H-cholesteryl ether (CEt) labelled HDL showed a 50% reduction in the 3H-CEt found in the LDL fraction in ciprofibrate treated compared to non-treated CETP mice. This means that 3H-CEt transferred from HDL to LDL was more efficiently removed from the plasma in the fibrate treated mice. Accordingly, the amount of 3H-CEt recovered in the liver 6 hours after HDL injection was increased by 35%. CONCLUSION: Together these data showed that the PPARalpha agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL.
Asunto(s)
Proteínas de Transferencia de Ésteres de Colesterol/genética , Colesterol/metabolismo , Ácido Clofíbrico/análogos & derivados , Hígado/metabolismo , Animales , Apolipoproteína C-III/farmacología , Transporte Biológico , Ácido Clofíbrico/farmacología , Ácidos Fíbricos , Expresión Génica/efectos de los fármacos , Hipertrigliceridemia/inducido químicamente , Ratones , PPAR alfa/agonistasRESUMEN
A series of 2-heteroarylthioalkanoic acids were synthesized through systematic structural modifications of clofibric acid and evaluated for human peroxisome proliferator-activated receptor alpha (PPARalpha) transactivation activity, with the aim of obtaining new hypolipidemic compounds. Some thiophene and benzothiazole derivatives showing a good activation of the receptor alpha were screened for activity against the PPARgamma isoform. The gene induction of selected compounds was also investigated in the human hepatoma cell line.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/farmacología , PPAR alfa/agonistas , Azufre/química , Línea Celular Tumoral , Ácido Clofíbrico/síntesis química , Ácido Clofíbrico/química , Humanos , Oxígeno/química , PPAR alfa/genética , Estereoisomerismo , Activación TranscripcionalRESUMEN
INTRODUCTION: Diabetic retinopathy is the leading cause of vision loss or blindeness in working-age adults in the developed and developing countries. No curative treatments are available for diabetic retinopathy and the most common symptomatic treatment, laser photocoagulation, provides only partial and temporary relief from the progressive vascular damage caused by this disease. Etofibrate (Lipo-Merz) is an orally-administered treatment for lipid disorders that combines fibrate and nicotinic acid in a slow-release formulation. PATIENTS AND METHODS: This report describes the results of a double-blind, randomised, placebo-controlled study, performed to evaluate the efficacy and safety of etofibrat in patients with type 2 diabetes mellitus and concomitant diabetic retinopathy. They received either placebo or 1000 mg/day etofibrate for up to 12 months. Efficacy analyses were based on visual acuity assessment and blinded expert ratings of ocular fundus pathology, as well as laboratory analyses of serum lipid parameters. RESULTS: The evaluable population comprised 296 patients, 148 in each treatment group, of whom 89% completed the study and 73% completed according to protocol. After 12 months of treatment, a significantly larger population of etofibrate-treated patients than placebo-treated patients showed improvements in ocular pathology (46% versus 32%, respectively, p < 0.001); similar findings were already apparent after 6 months of treatment (43% versus 31%, respectively p < 0.001). Etofibrate treatment also produced significant improvements in total cholesterol, LDL-cholesterol and HDL-cholesterol in comparison to the placebo treatment group. Safety evaluations (adverse events, laboratory parameters) did not reveal any clinically significant adverse effects of etofibrate in comparison to placebo. CONCLUSION: Etofibrate provides a safe and effective treatment for ocular pathology resulting from type 2 diabetes mellitus.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Retinopatía Diabética/complicaciones , Retinopatía Diabética/tratamiento farmacológico , Administración Oral , Adolescente , Adulto , Anciano , Ácido Clofíbrico/administración & dosificación , Ácido Clofíbrico/efectos adversos , Método Doble Ciego , Femenino , Humanos , Hipolipemiantes/administración & dosificación , Hipolipemiantes/efectos adversos , Masculino , Persona de Mediana Edad , Efecto Placebo , Resultado del Tratamiento , Adulto JovenRESUMEN
Perfluorooctanesulfonamides, such as N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), are large scale industrial chemicals but their disposition and toxicity are poorly understood despite significant human exposure. The hypothesis that subacute exposure to N-EtFOSE, a weak peroxisome proliferator, causes a redox imbalance in vivo was tested using the known peroxisome proliferator, ciprofibrate, as a positive control. Female Sprague-Dawley rats were treated orally with N-EtFOSE, ciprofibrate or corn oil (vehicle) for 21 days, and levels of N-EtFOSE and its metabolites as well as markers of peroxisome proliferation and oxidative stress were assessed in serum, liver and/or uterus. The N-EtFOSE metabolite profile in liver and serum was in good agreement with reported in vitro biotransformation pathways in rats and the metabolite levels decreasing in the order perfluorooctanesulfonate >> perfluorooctanesulfonamide ~ N-ethyl perfluorooctanesulfonamidoacetate >> perfluorooctanesulfonamidoethanol approximately N-EtFOSE. Although N-EtFOSE treatment significantly decreased the growth rate, increased relative liver weight and activity of superoxide dismutases (SOD) in liver and uterus (total SOD, CuZnSOD and MnSOD), a metabolic study revealed no differences in the metabolome in serum from N-EtFOSE-treated and control animals. Ciprofibrate treatment increased liver weight and peroxisomal acyl Co-A oxidase activity in the liver and altered antioxidant enzyme activities in the uterus and liver. According to NMR metabolomic studies, ciprofibrate treated animals had altered serum lipid profiles compared to N-EtFOSE-treated and control animals, whereas putative markers of peroxisome proliferation in serum were not affected. Overall, this study demonstrates the biotransformation of N-EtFOSE to PFOS in rats that is accompanied by N-EtFOSE-induced alterations in antioxidant enzyme activity.
Asunto(s)
Ácidos Alcanesulfónicos/metabolismo , Contaminantes Ambientales/toxicidad , Fluorocarburos/metabolismo , Hidrocarburos Fluorados/toxicidad , Sulfonamidas/toxicidad , Superóxido Dismutasa/metabolismo , Acil-CoA Oxidasa , Ácidos Alcanesulfónicos/química , Animales , Biomarcadores/metabolismo , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/sangre , Contaminantes Ambientales/sangre , Contaminantes Ambientales/química , Femenino , Ácidos Fíbricos , Fluorocarburos/química , Hidrocarburos Fluorados/sangre , Hidrocarburos Fluorados/química , Hígado/metabolismo , Oxidorreductasas/metabolismo , Ratas , Ratas Sprague-Dawley , Sulfonamidas/sangre , Sulfonamidas/química , Superóxido Dismutasa/efectos de los fármacos , Pruebas de Toxicidad , Útero/metabolismoRESUMEN
Etofibrate, a combination of fibric and nicotinic acid, is successfully used for the treatment of type IIb and IV hyperlipidemia. While an up-regulation of specific low density lipoproteins (LDL) binding sites in human platelets has been demonstrated, action on LDL-binding to the liver in patients and kinetic studies rare. This study aimed to investigate the influence of twice 500mg etofibrate daily given for 6 weeks on the in vivo binding of autologous LDL to the liver in 11 patients, 6 males, 5 females; aged 37-57 years, suffering from mixed hyperlipidemia. Etofibrate enhanced in vivo liver uptake of (123)I-LDL by 16.1% at mean, shortened plasma decay of LDL and improved lipid profile: serum total cholesterol was lowered by 14.9%, LDL-cholesterol was lowered by 22.2% and high-density lipoprotein (HDL)- cholesterol was increased by 10.9%. These findings are documenting a beneficial effect of the drug at the LDL liver receptor level in vivo.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Hiperlipidemias/tratamiento farmacológico , Hiperlipidemias/metabolismo , Lipoproteínas LDL/farmacocinética , Hígado/metabolismo , Adulto , Ácido Clofíbrico/administración & dosificación , Esquema de Medicación , Sinergismo Farmacológico , Femenino , Humanos , Hiperlipidemias/diagnóstico por imagen , Hipolipemiantes/administración & dosificación , Radioisótopos de Yodo/farmacocinética , Hígado/diagnóstico por imagen , Hígado/efectos de los fármacos , Masculino , Persona de Mediana Edad , Unión Proteica/efectos de los fármacos , Cintigrafía , Radiofármacos/farmacocinética , Resultado del TratamientoRESUMEN
Seasonal obesity and fasting-associated hibernation are the two major metabolic events governing hepatic lipid metabolism in hibernating mammals. In this process, however, the role of the nuclear receptor known as peroxisome proliferator-activated receptor (PPAR)-alpha has not been elucidated yet. Here we show, as in human, that jerboa (Jaculus orientalis) liver expresses both active wild-type PPARalpha (PPARalpha1wt) and truncated PPARalpha forms and that the PPARalpha1wt to truncated PPARalpha2 ratio, which indicates the availability of active PPARalpha1wt, is differentially regulated during fasting-associated hibernation. Functional activation of hepatic jerboa PPARalpha, during prehibernating and hibernating states, was demonstrated by the induction of its target genes, which encode peroxisomal proteins such as acyl-CoA oxidase 1, peroxisomal membrane protein 70, and catalase, accompanied by a concomitant induction of PPARalpha thermogenic coactivator PPARgamma coactivator-1alpha. Interestingly, sustained activation of PPARalpha by its hypolipidemic ligand, ciprofibrate, abrogates the adaptive fasting response of PPARalpha during prehibernation and overinduces its target genes, disrupting the prehibernation fattening process. In striking contrast, during fasting-associated hibernation, jerboas exhibit preferential up-regulation of hepatic peroxisomal fatty acid oxidation instead of the mitochondrial pathway, which is down-regulated. Taken together, our results strongly suggest that PPARalpha is subject to a hibernation-dependent splicing regulation in response to feeding-fasting conditions, which defines the activity of PPARalpha and the activation of its target genes during hibernation bouts of jerboas.
Asunto(s)
Ayuno/fisiología , Ácidos Grasos/metabolismo , Hibernación/genética , Hígado/metabolismo , PPAR alfa/genética , Roedores/genética , Roedores/metabolismo , Adaptación Fisiológica/efectos de los fármacos , Adaptación Fisiológica/genética , Adaptación Fisiológica/fisiología , Animales , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/farmacología , Ayuno/metabolismo , Ácidos Fíbricos , Regulación de la Expresión Génica/efectos de los fármacos , Hibernación/fisiología , Hipolipemiantes/farmacología , Metabolismo de los Lípidos/genética , Mamíferos , Oxidación-Reducción , PPAR alfa/metabolismo , Peroxisomas/metabolismo , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
Etofibrate, fenofibrate, and atorvastatin were determined in their pharmaceutical preparations and human plasma using differential pulse polarographic and square wave voltammetric techniques by reduction at a dropping-mercury working electrode versus Ag/AgCl reference electrode. The reversibility of the electrode reactions was tested using cyclic voltammetry, and they were found to be irreversible reduction reactions. Optimum conditions such as pH, scan rate, and pulse amplitude were studied, and validation of the proposed methods was performed. The proposed methods proved to be accurate, precise, robust, and specific for determination of the 3 drugs. The relative standard deviation values were <2%, indicating that these methods are precise. Limits of detection and quantitation were in the ranges of 0.037-0.21 and 0.12-0.71 microg/mL, respectively, indicating high sensitivity.
Asunto(s)
Anticolesterolemiantes/análisis , Ácido Clofíbrico/análogos & derivados , Fenofibrato/análisis , Ácidos Heptanoicos/análisis , Hipolipemiantes/análisis , Pirroles/análisis , Anticolesterolemiantes/sangre , Atorvastatina , Ácido Clofíbrico/análisis , Ácido Clofíbrico/sangre , Electroquímica , Fenofibrato/sangre , Ácidos Heptanoicos/sangre , Humanos , Concentración de Iones de Hidrógeno , Hipolipemiantes/sangre , Indicadores y Reactivos , Polarografía , Pirroles/sangre , Estándares de Referencia , Reproducibilidad de los Resultados , SolucionesRESUMEN
Fibrates are widely prescribed in hyperlpidemic patients to prevent atherosclerosis. Their therapeutic use, however, can be associated with adverse effects like gastrointestinal disorders, myalgia, myositis and hepatotoxicity. In rodents large doses can even cause hepatocellular carcinoma. Additionally, interactions with the biotransformation of other compounds at the cytochrome P450 (CYP) system have been observed. Thus, the discovery of new substances or derivatives with less side effects is of great interest. In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats. Although obese rats displayed distinctly higher serum lipid concentrations, after fibrate treatment values were significantly lowered in lean animals only. Livers of obese rats were significantly enlarged, histologically showing a fine-droplet like fatty degeneration and an increase in glycogen content, but no signs of inflammation. After fibrate administration histologically a hypertrophy, an eosinophilia, a reduced glycogen content and also hepatocyteapoptosis were observed. Livers of obese rats displayed higher CYP1A1 andCYP2E1 expression, but lower immunostaining for CYP2B1 and CYP3A2. No differences between the two groups of rats were seen with respect to CYP4A1 expression. Due to fibrate treatment especially CYP2E1 and CYP4A1, but also CYP1A1, 2B1 and 3A2 were induced. Resulting CYP mediated monooxygenase activities were also elevated in most cases. In general, effects of clofibric acid and clofibric acid glycinate (CAS 4896-55-3) were less distinct than those of ciprofibrate and its glycinate (CAS 640772-36-7). With no parameterinvestigated major differences were seen between the parent fibrates and their glycine conjugates. Thus, the present investigations revealed no noticeable advantages of the glycinates over ciprofibrate or clofibric acid.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/farmacología , Hipolipemiantes/farmacología , Obesidad/tratamiento farmacológico , Animales , Peso Corporal/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Ácido Clofíbrico/toxicidad , Sistema Enzimático del Citocromo P-450/metabolismo , Ácidos Fíbricos , Glicina/farmacología , Hidroxiprolina/metabolismo , Hipolipemiantes/toxicidad , Inmunohistoquímica , Isoenzimas/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Masculino , Síndrome Metabólico/tratamiento farmacológico , Oxigenasas de Función Mixta/metabolismo , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Zucker , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismoRESUMEN
Pigment epithelium-derived factor (PEDF) is an endogenous antiangiogenic protein that also possesses antitumor activity. The mechanisms by which PEDF exerts its actions remains poorly understood. We sought to understand the role of PEDF in hepatocellular carcinoma (HCC), a hypervascular malignancy that has been shown to upregulate enzymes involved in fatty acid synthesis. PEDF expression occurs in two HCC cell lines and is oxygen dependent. Migration studies confirm PEDF's role as an endogenous inhibitor of angiogenesis in HCC cells. Loss of PEDF in an animal model leads to hepatocyte lipid accumulation, proliferation, and cellular atypia. To investigate potential interactions with transcription factors that are involved in fatty acid metabolism and cellular proliferation, we examined PEDF's interaction with PPARalpha in vitro and its functional activity through transactivation assays. We show that PEDF binds to PPARalpha but minimally to PPARgamma. In the presence of the ligand, ciprofibrate, PEDF binding to PPARalpha decreases whereas the presence of troglitazone does not alter PEDF interactions with PPARgamma. Transfection of the PEDF gene in the presence of the PPARalpha/RXR heterodimer demonstrates transcriptional activation of PPARalpha by PEDF. These data show that PEDF regulates lipid metabolism through activation of the transcription factor PPARalpha.
Asunto(s)
Carcinoma Hepatocelular/irrigación sanguínea , Proteínas del Ojo/metabolismo , Metabolismo de los Lípidos , Neoplasias Hepáticas/irrigación sanguínea , Neovascularización Patológica/patología , Factores de Crecimiento Nervioso/metabolismo , PPAR alfa/metabolismo , Serpinas/metabolismo , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Hipoxia de la Célula , Movimiento Celular/fisiología , Cromanos/farmacología , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/farmacología , Endotelio Vascular/citología , Ácidos Fíbricos , Humanos , Hipoglucemiantes/farmacología , Hipolipemiantes/farmacología , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , PPAR gamma/metabolismo , Tiazolidinedionas/farmacología , Troglitazona , Células Tumorales CultivadasRESUMEN
Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands evoke a profound mitogenic response in rodent liver, and the aim of this study was to characterize the kinetics of induction of DNA synthesis. The CAR ligand, 1,4-bis[2-(3,5-dichoropyridyloxy)]benzene, caused induction of hepatocyte DNA synthesis within 48 h in 129S4/SvJae mice, but the potent PPARalpha ligand, ciprofibrate, induced hepatocyte DNA synthesis only after 3 or 4 days dosing; higher or lower doses did not hasten the DNA synthesis response. This contrasted with the rapid induction (24 h) reported by Styles et al., 1988, Carcinogenesis 9, 1647-1655. C57BL/6 and DBA/2J mice showed significant induction of DNA synthesis after 4, but not 2, days ciprofibrate treatment. Alderley Park and 129S4/SvJae mice dosed with methylclofenapate induced hepatocyte DNA synthesis at 4, but not 2, days after dosing and proved that inconsistency with prior work was not due to a difference in mouse strain or PPARalpha ligand. Ciprofibrate-induced liver DNA synthesis and growth was absent in PPARalpha-null mice and are PPARalpha dependent. In the Fisher344 rat, hepatocyte DNA synthesis was induced at 24 h after dosing, with a second peak at 48 h. Lobular localization of hepatocyte DNA synthesis showed preferential periportal induction of DNA synthesis in rat but panlobular zonation of hepatocyte DNA synthesis in mouse. These results characterize a markedly later hepatic induction of panlobular DNA synthesis by PPARalpha ligands in mouse, compared to rapid induction of periportal DNA synthesis in rat.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , ADN/metabolismo , Hepatocitos/efectos de los fármacos , Hígado/efectos de los fármacos , PPAR alfa/metabolismo , Proliferadores de Peroxisomas/farmacología , Animales , Ácido Clofíbrico/farmacología , Ácidos Fíbricos , Hepatocitos/metabolismo , Cinética , Ligandos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos DBA , Ratones Transgénicos , Ratas , Ratas Endogámicas F344 , Especificidad de la EspecieRESUMEN
It is well known that the hypolipidemic drug ciprofibrate induces peroxisome proliferation in rodent liver, which in turn leads to the oxidative stress, and modifies some parameters related to cell proliferation and apoptosis. The administration of ciprofibrate to rats during the lactating period determined in their pups significant modifications in hepatic peroxisome enzyme activities, induction of the PPARalpha-target gene, Cyp4a10, and perturbation in cell proliferation and apoptosis, which affected the size of the liver. Moreover, this modification was associated to about two-fold induction of mRNA-PPARalpha. On the contrary, in the kidney, although a similar two-fold up-regulation of PPARalpha was detected, the induction of both peroxisomal enzyme activities and Cyp4a10 were weak, and no alterations were detected, neither in cell cycle nor in the size of the tissue. Our results indicate that the response to ciprofibrate is stronger in the liver than in the kidney of newborn rats.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Hipolipemiantes/toxicidad , Riñón/efectos de los fármacos , Lactancia/efectos de los fármacos , Hígado/efectos de los fármacos , PPAR alfa/metabolismo , Animales , Animales Recién Nacidos , Animales Lactantes , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Ácido Clofíbrico/toxicidad , Citocromo P-450 CYP4A/biosíntesis , Citocromo P-450 CYP4A/genética , Femenino , Ácidos Fíbricos , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Riñón/metabolismo , Hígado/metabolismo , Hígado/patología , Exposición Materna , Tamaño de los Órganos/efectos de los fármacos , PPAR alfa/genética , Embarazo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Transducción de SeñalRESUMEN
Peroxisome proliferators (PPs) are a diverse class of chemicals, which cause a dramatic increase in the size and number of hepatic peroxisomes in rodents and eventually lead to the development of hepatic tumors. Nuclear factor-kappaB (NF-kappaB) is a transcription factor activated by reactive oxygen and is involved in cell proliferation and apoptosis. Previously we found that the peroxisome proliferator ciprofibrate (CIP) activates NF-kappaB and that dietary vitamin E decreases CIP-induced NF-kappaB DNA binding. We, therefore, hypothesized that inhibition of NF-kappaB by vitamin E is necessary for effects of vitamin E on CIP-induced cell proliferation and the inhibition of apoptosis by CIP. Sixteen B6129 female mice (p50+/+) and twenty mice deficient in the p50 subunit of NF-kappaB (p50-/-) were fed a purified diet containing 10 or 250mg/kg vitamin E (alpha-tocopherol acetate) for 28 days. At that time, half of the mice were placed on the same diet with 0.01% CIP for 10 days. CIP treatment increased the DNA binding activity of NF-kappaB and cell proliferation, but had no significant effect on apoptosis. Compared to wild-type mice, the p50-/- mice had lower NF-kappaB activation, higher basal levels of cell proliferation and apoptosis, and a lower ratio of reduced glutathione to oxidized glutathione (GSH/GSSG). There was approximately a 60% reduction in cell proliferation in the CIP-treated p50-/- mice fed higher vitamin E in comparison to the p50-/- mice fed lower vitamin E. Dietary vitamin E also inhibited the DNA binding activity of NF-kappaB, increased apoptosis, and increased the GSH/GSSG ratio. This study shows the effects of vitamin E on cell growth parameters do not appear to be solely through decreased NF-kappaB activation, suggesting that vitamin E is acting by other molecular mechanisms.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Subunidad p50 de NF-kappa B/fisiología , Proliferadores de Peroxisomas/farmacología , Vitamina E/farmacología , Acil-CoA Oxidasa/metabolismo , Animales , Apoptosis/efectos de los fármacos , Western Blotting , Peso Corporal/efectos de los fármacos , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Ácido Clofíbrico/farmacología , Ciclinas/biosíntesis , ADN/biosíntesis , ADN/genética , Dieta , Ensayo de Cambio de Movilidad Electroforética , Femenino , Ácidos Fíbricos , Glutatión/metabolismo , Hígado/enzimología , Hígado/metabolismo , Ratones , Ensayos de Protección de Nucleasas , Tamaño de los Órganos/efectos de los fármacos , ARN/biosíntesis , ARN/genética , Factor de Transcripción ReIA/metabolismoRESUMEN
Some new organometallics of ruthenium(II) of the type [RuCl2(COD)(CO)L] (1a-f) and [RuCl2(COD)L2] (2a-f) (where L is substituted tertiary phosphines), have been synthesized by using precursors [RuCl2(COD)(CO)(CH3CN)] (1) and [RuCl2(COD)(CH3CN)2] (2) with the substituted tertiary phosphine ligands in 1:1 and 1:2 molar ratio. The organometallics (2a-f) have been further reacted with carbonmonoxide to produce compounds of the type [RuCl2(CO)L2] (3a-f). These compounds were characterized by elemental analysis, IR, NMR (1H, 13C and 31P), mass and electronic spectral data. The catalytic activity of all these organometallics were studied and found that they are efficient catalysts for hydrolysis of etofibrate. The hydrolyzed product was separated by column chromatography and the percent yields are found in the range of 98.6-99.1%.
Asunto(s)
Ácido Clofíbrico/análogos & derivados , Compuestos Organometálicos/química , Preparaciones Farmacéuticas , Fosfinas/química , Compuestos de Rutenio/química , Catálisis , Fenómenos Químicos , Química Física , Ácido Clofíbrico/química , Electrones , Hidrólisis , Análisis EspectralRESUMEN
Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists have been reported to induce apoptosis in a variety of cell types including renal proximal epithelial cells. However, the underlying mechanism of cell death induced by PPARgamma agonists has not been clearly defined in renal proximal tubular cells. This study was therefore undertaken to determine the mechanism by which ciglitazone, a synthetic PPARgamma agonist, induces apoptosis in opossum kidney (OK) cells, an established renal epithelial cell line. Ciglitazone treatment induced apoptotic cell death in a dose- and time-dependent manner. Ciglitazone caused a transient activation of ERK and sustained activation of p38 MAP kinase. Ciglitazone-mediated cell death was attenuated by the p38 inhibitor SB203580 and transfection of dominant-negative form of p38, but not by the MEK inhibitor U0126, indicating that p38 MAP kinase activation is involved in the ciglitazone-induced cell death. Although ciglitazone-induced caspase-3 activation, the ciglitazone-mediated cell death was not affected by the caspase-3 inhibitor DEVD-CHO. Ciglitazone-induced mitochondrial membrane depolarization and apoptosis-inducing factor (AIF) nuclear translocation and these effects were prevented by the p38 inhibitor. These results suggest that ciglitazone induces caspase-independent apoptosis through p38 MAP kinase-dependent AIF nuclear translocation in OK renal epithelial cells.